Atara Biotherapeutics (ATRA) Return on Capital Employed (2014 - 2026)
Atara Biotherapeutics (ATRA) reported Return on Capital Employed of 243.94% for Q1 2026, down 20840.0% on a YoY basis from N/an in Q1 2025, and down 464.93% quarter-over-quarter from 66.85% in Q4 2025.
Atara Biotherapeutics (ATRA) Return on Capital Employed (2014 - 2026) Analysis & Trends
Atara Biotherapeutics has reported Return on Capital Employed for 13 years, with the latest figure at 243.94% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 20840.0% year-over-year to 243.94%; the trailing twelve-month figure through Mar 2026 stood at 243.94% (down 20840.0% YoY), and the FY2025 full-year result was 13.81%, up 307351.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 243.94%, down from 66.85% in the prior quarter.
- The five-year high for Return on Capital Employed was 2561.91% in Q2 2024, with the low at 790.4% in Q4 2023.
- Historically, Return on Capital Employed has averaged 229.22% across 5 years, with a median of 85.06% in 2022.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 271543 bps — and 2025, when it sank 253888 bps.
- Atara Biotherapeutics' Return on Capital Employed stood at 95.59% in 2022, then plunged by 727 bps to 790.4% in 2023, then surged by 222 bps to 962.15% in 2024, then tumbled by 93 bps to 66.85% in 2025, then sank by 465 bps to 243.94% in 2026.
- The last three Return on Capital Employed figures came in at 243.94% (Q1 2026), 66.85% (Q4 2025), and 169.42% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Atara Biotherapeutics | 134.61 Mn | 126.21 Mn | 392,000.00 | -243.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -243.94% |
| Dec 31, 2025 | 66.85% |
| Sep 30, 2025 | 169.42% |
| Jun 30, 2025 | 23.03% |
| Mar 31, 2025 | -35.54% |
| Dec 31, 2024 | 962.15% |
| Sep 30, 2024 | 504.91% |
| Jun 30, 2024 | 2,561.91% |
| Mar 31, 2024 | 1,517.68% |
| Dec 31, 2023 | -790.40% |
| Sep 30, 2023 | -210.49% |
| Jun 30, 2023 | -153.52% |
| Mar 31, 2023 | -98.50% |
| Dec 31, 2022 | -95.59% |
| Sep 30, 2022 | -90.42% |
| Jun 30, 2022 | -85.06% |
| Mar 31, 2022 | -105.83% |
| Dec 31, 2021 | -96.38% |
| Sep 30, 2021 | -89.53% |
| Jun 30, 2021 | -78.80% |